Circular RNA_0078767 upregulates Kruppel-like factor 9 expression by targeting microRNA-889, thereby inhibiting the progression of osteosarcoma

Qiu Chen*, Haisen Zhou ab, and Weihao Rongc

*Medical College, Yangzhou University, Yangzhou 225009, Jiangsu, China; aDepartment of Pathology, Lishui Hospital of Chinese Medicine Affiliated to Yangzhou University Medical College, Nanjing 211299, Jiangsu, China; bDepartment of Orthopedics, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing 211299, Jiangsu, China

ABSTRACT
Among kids and juveniles, osteosarcoma (OS) is a common bone malignancy. Circular RNAs (circs, circRNAs) play important roles in multiple malignancies including OS, yet circ_0078767’s biological functions in OS are far from well elucidated. This study is targeted at understanding circ_0078767’s biological functions in OS and its molecular mechanisms. This study confirmed that circ_0078767 expression was reduced in OS cell lines and tissues. Circ_0078767 overexpression remarkably inhibited OS cell growth, migration, invasion, epithelial-mesenchymal transition (EMT), and promoted apoptosis, whereas circ_0078767 knockdown resulted in the opposite effects. MicroRNA-889 (miR-889) was targeted and regulated by circ_0078767, and miR-889 could negatively modulate Kruppel-like factor 9 (KLF9) expression. Besides, circ_0078767 positively regulated KLF9 expression in OS cells via repressing miR-889. In conclusion, circ_0078767 enhances KLF9 expression by targeting miR-889 to inhibit OS progression.

1. Introduction
Recognized as a common primary bone tumor and the third commonest malignancy among adolescents and children, osteosarcoma (OS) has a high recurrence rate, a high degree of malignancy and high metastatic potential [1]. The preferred treatment strategy for OS is surgical excision, com-
bined with systemic chemotherapy [2]. For the last few years, OS patients’ survival rate has been elevated, yet the overall survival rate of patients with distant metastasis and recurrence remains under 20% [3]. In this context, exploring the mechanism of OS pathogenesis and seeking effective novel therapy targets are highly significant for improving OS patients’ prognosis.

As a type of endogenous non-coding RNA, circular RNAs (circRNAs) show characteristics such as high abundance, evolutionary conservation, specific expression in different cells and tissues, and so on [4,5]. Abnormally expressed circRNAs are involved in tumorigenesis and cancer progression. For instance, circ_0049027 overexpression restraints gastric cancer cell migration, growth and invasion [6]; circ_0030586 promotes epithelial-mesenchymal transition (EMT) in prostate cancer cells through PI3K/AKT signaling [7]. In OS, knocking down circRNA_100876 promotes OS cell apoptosis and blocks cell cycle progression [8]; overexpression of circTADA2A facilitates OS cell growth and metastasis and inhibits the apoptosis via increasing cAMP-responsive element-binding protein 3 expression [9]. The bioinformatics analysis in this study implied that in OS tissues circ_0078767 was downregulated, yet circ_0078767’s biological functions in OS are not well understood.

MicroRNAs (miRs, miRNAs) are highly conserved short endogenous non-coding RNAs which can modulate target gene expression negatively at post-transcriptional level [10]. MiRNAs mainly bind with mRNA 3′-untranslated region (3′-UTR) to repress the translation [11]. A lot of miRNAs are differentially expressed in OS tissues, and are involved in cancer progression [12]. For instance, miR-221 expression in the tumor tissues of OS patients is significantly higher as against the non-cancerous tissues, and its expression is strongly linked to the tumor stage, metastasis status, and response to chemotherapy [13]. Reportedly, miR-889-3p can target and suppress myeloid cell nuclear differentiation antigen to promote OS cell proliferation [14]. Nevertheless, the molecular mechanism of miR-889 by which it promotes the malignancy of OS cells has not been fully clarified yet.

Kruppel-like factor 9 (KLF9), also known as basic transcription element-binding protein 1 (BTEB1), regulates a variety of biological processes, including cell proliferation, differentiation and apoptosis [15]. KLF9 can inhibit the progression of OS [16]. In addition, the miR-889/KLF9 axis has been found to play a key role in the pathogenesis of non-small cell lung cancer and breast cancer [17,18]. However, it is unclear whether the miR-889/KLF9 axis is involved in OS progression.

Here, we hypothesize that circ_0078767 plays a tumor-suppressive role in OS by acting as a molecular sponge for miR-889 to regulate KLF9 expression. The aim of this study is to explore the expression, functions and potential mechanisms of circ_0078767 in OS. The current study suggests that circ_0078767 may be a potential target for OS therapy.

2. Materials and methods
2.1 Bioinformatics analysis

The microarray dataset GSE87449 was downloaded from the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) database. In GSE87449, circRNA expression profiles in 3 pairs of para-cancerous tissues and OS tissues were compared. Screening criteria: $P < 0.05$ and $|\log2(\text{fold change})| > 1$ [19]. The Circular RNA Interactome database (https://circinteractome.nia.nih.gov/) was used to predict the target miRNAs of circ_0078767. The starBase database (http://starbase.sysu.edu.cn/) was used to predict the potential targets of miR-889.

2.2 Clinical samples

Forty-four pairs of OS and para-cancerous tissues used in the present study were all provided by the human tissue bank of Yangzhou University. Each participant signed informed consent, and none of the subjects received any neoadjuvant therapy, such as radiotherapy or chemotherapy before surgery. All tissues were stored in $-196^\circ\text{C}$ liquid nitrogen after surgical removal. The research program was endorsed by the Science and Research Ethics Committee of Yangzhou University (approval number: YZUHL2019008) (Supplementary document).
2.3. Quantitative real-time polymerase chain reaction (qRT-PCR)

The total RNA of OS cells and tissues was extracted utilizing TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The Cytoplasmic & Nuclear RNA Purification Kit (Amyjet, Wuhan, China) was used to extract RNA from the nucleus or cytoplasm of OS cells, respectively. The PrimeScript RT kit and the One Step PrimeScript miRNA complementary DNA (cDNA) synthesis kit (Takara, Tokyo, Japan) were employed for the reverse transcription of the RNA into cDNA. Using the SYBR Premix Ex Taq II kit (Takara, Tokyo, Japan), qRT-PCR was performed on the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The 2^{-ΔΔCt} method was employed for calculating the relative expression of target genes in each experimental group, with U6 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal references [20]. Table 1 shows the primer sequences.

2.4. Cell culture and transfection

From the American Type Culture Collection (Rockville, MD, USA), we bought OS cell lines (MG63, HOS, SJSA1, Saos2, U2OS and KH-OS) and normal osteoblast cell line (hFOB1.19). These cells were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) with 0.1 mg/mL streptomycin and 100 U/mL penicillin (ThermoFisher Scientiﬁc, Shanghai, China) and 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) at 37°C in 5% CO₂. We observed the cell growth routinely, and refreshed the medium every 2 to 3 days. Cells in the logarithmic phase were passaged with 0.25% trypsin (HyClone, Logan, UT, USA). Empty plasmid (NC), circ_0078767 overexpression plasmids (circ_0078767), KLF9 overexpression plasmids (KLF9), small interfering RNA (siRNA) negative control (si-NC), siRNAs against circ_0078767 (si-circ_0078767#1, si-circ_0078767#2 and si-circ_0078767#3), miR-889 mimics and inhibitors, mimics control (miR-NC) and inhibitors control (miR-in) were all designed and synthesized by GenePharma (Shanghai, China) [21]. According to the manufacturer’s instructions, the cell transfection was conducted employing Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA). All oligonucleotide sequences are listed in Table 2.

2.5. Ribonuclease (RNase) R treatment

For RNase R treatment, 2 μg of RNA was incubated with RNase R (3 U/μg) (Epicenter, Madison, WI, USA) for 30 min at 37°C [22]. Next, qRT-PCR was used to detect the expression of circ_0078767.

2.6. Actinomycin D assay

Actinomycin D assay was performed as previously described [23]. Briefly, Saos2 and MG63 cells were inoculated in six-well plates at a density of 1 × 10^5 cells/well and cultured for 24 h. Fresh medium supplemented with 2 μg/mL actinomycin D (Sigma-Aldrich, Beijing, China) was then added. Total cellular RNA was extracted for qRT-PCR analysis at 0, 8, 16 and 24 h after actinomycin D treatment.

2.7. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

As previously described [24], the transfected MG63 and Saos2 cells were trypsinized and

| Name | Sequence (5'-3') |
|------|------------------|
| circ_0078767 | F: TGCTAGCTGTCAAGGAGGTG |
| circ_0078767 | R: GGATCTAGAGATGCCCAACA |
| GAPDH | F: TGGATACGTTGGAAGGATC |
| GAPDH | R: AGTACGACGAGGATGATG |
| KLF9 | F: ACAGTGGCTGGAGAAATGC |
| KLF9 | R: TCAAAAGCGTGGCCAGGG |
| miR-889 | F: ACACCCCATGGTATGTATACCCGACAC |
| miR-889 | R: TGCTGGCGTGGATGATG |
| U6 | F: CTGCTTCCGCCAGACA |
| U6 | R: AAGCGCTTCCAGGATTTGCG |

F, forward; R, reverse.

Table 2. The oligonucleotides transfected in this study are listed as follows.

| Oligonucleotide | Sequence (5'-3') |
|----------------|------------------|
| si-NC | CAGATAAGAAATGTATTT |
| si-circ_0078767#1 | AGATGACCTACCCAGGTGCAAGCA |
| si-circ_0078767#2 | ACCATCCAGGTAAGCAGGGAAGCA |
| si-circ_0078767#3 | ATGACCTACCCAGGTAAGCAGGGAAGCA |
| miR-889 mimics | UUAUAUUGGACAAACAUUUG |
| miR-NC | UUUCCGGAAGUUGCAGGU |
| miR-889 inhibitors | ACAUUUGGUGUCCGAUUA |
| miR-in | CAGUAUUUUUGGUGUAUACAA |

| Table 1. Primers used for qRT-PCR. |
inoculated into 96-well plates (2 × 10^3 cells/well), and then the cells were routinely cultured. Subsequently, on days 0, 1, 2, 3 and 4, each well was added with 10 μL of 5 mg/mL MTT solution (Beyotime Biotechnology, Shanghai, China), and the cells were incubated in 5% CO₂ for 4 h at 37°C. Next, the supernatant was discarded, and each well was added with 200 μL of dimethyl sulfoxide (Sigma-Aldrich, Beijing, China) to dissolve the formazan. Ultimately, a microplate reader was adopted for determining the optical density (OD) at 570 nm of each well.

2.8. Scratch wound healing assay

Scratch wound healing assays were performed as previously described [25]. MG63 and Saos2 cells were inoculated into 6-well plates at 2 × 10^5 cells/well, and cultured to about 90% confluency. Next, we used the tip of a pipette to scratch the cell layer, and the cells were then rinsed three times with phosphate buffer saline (PBS) to remove the debris. Next, the cells were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) without FBS. The light microscope was used to take pictures, and the width of the scratch was recorded at 0 and 24 h, respectively.

2.9. Transwell invasion assay

Cell invasion was examined using the Transwell assay as previously described [26]. The experiment was carried out with the Transwell chamber (8-μm pore size; Costar, Corning, NY, USA), which was coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Each well was added with 600 μL of 10% FBS-containing RPMI-1640 medium, and OS cells (2 × 10^5 cells/well) were inoculated in the top compartment. Cotton swabs were utilized, after 48 h of incubating, to remove the OS cells on the filter’s upper surface, and the cells having invaded into the bottom compartment were fixed with 4% paraformaldehyde and stained with crystal violet solution. In 5 randomly chosen fields under the microscope, the OS cells were photographed and counted.

2.10. Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay

Cell apoptosis was detected employing the One-step TUNEL Apoptosis Detection Kit (Beyotime, Shanghai, China) as previously described [27]. Briefly, cells growing on glass slides were fixed with 4% paraformaldehyde at room temperature. After washing with PBS, the cells were incubated with 0.3% H₂O₂ solution to block endogenous peroxidase activity. The cells were then incubated with TUNEL reaction solution for 1 h at 37°C, and the nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (Beyotime, Shanghai, China) for 1 min at room temperature. Apoptotic cells were indicated by the nick ends marked in green, and the number of apoptotic cells was observed and counted by an Olympus IX70 inverted microscope (Olympus, Tokyo, Japan).

2.11. Xenograft model

The animal experiments were approved by the Animal Ethics Committee of Yangzhou University and conducted in accordance with the guidelines of the National Society for Animal Protection and Ethics. Female BALB/c nude mice (n = 20, age: 5–6 weeks) were provided by the Experimental Animal Center of Yangzhou University (Jiangsu, China). Mice were randomly divided into a si-NC/MG63 group and a si-circ_0078767#2/MG63 group, with 10 mice in each group. In the lung metastasis assay, MG63 cells with circ_0078767 knockdown as well as control cells (1 × 10^7 cells per mouse) were injected into the nude mice via the caudal vein. Two weeks later, the mice were euthanized and their lungs were collected for pathological examination. Hematoxylin-eosin (HE) staining was performed, and the section was observed to assess the degree of lung metastasis [28].

2.12. Dual-luciferase reporter gene assay

The dual-luciferase reporter gene assay was performed as previously described [29]. Circ_0078767 or KLF9 3'-UTR fragments with the miR-889 binding sites were amplified and integrated into
the pmirGLO reporter vector (Promega Corp., Madison, WI, USA) to establish the pmirGLO-circ_0078767 wild type (circ_0078767-WT) or pmirGLO-KLF9 wild type (KLF9-WT) reporter vector. Saos2 and MG63 cells were co-transfected with miR-889 mimics or miR-NC and the above-mentioned luciferase reporter vectors utilizing Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA). The dual-luciferase reporter gene detection system (Promega, Madison, WI, USA) was employed 48 h after the transfection to determine the luciferase activity.

2.13. RNA immunoprecipitation (RIP) assay

The Magna RIP kit (Millipore, Bedford, MA, USA) was adopted for RIP assay according to the manufacturer's instructions. Saos2 and MG63 cells were lysed by RIP lysis buffer (Beyotime, Shanghai, China) as previously described [30]. The whole cell extract (100 μL) and radio-immunoprecipitation assay (RIPA) buffer (Beyotime, Shanghai, China) were incubated together. The magnetic beads pre-coated with anti-argonaute 2 protein (Ago2) antibody (Abcam, Shanghai, China) were added to interact with circ_0078767-miR-889 complex, and anti-immunoglobulin G (IgG) antibody (Millipore, Bedford, MA, USA) served as the control. After the immunoprecipitate and proteinase K were incubated to remove the protein, qRT-PCR was utilized to determine the relative enrichment of circ_0078767 in the immunoprecipitate.

2.14. RNA pull-down assay

Biotin-labeled RNA pull-down experiments were performed as previously described [31]. Briefly, Saos2 and MG63 cells were transfected with biotinylated miR-889 (Bio-miR-889) and the control (Bio-miR-NC) and then cultured for 24 h. Whole cell lysates were collected and mixed with streptavidin-Dynabeads (Invitrogen, Carlsbad, CA, USA) and incubated at 4°C with rotation overnight. After washing the beads with wash buffer, bead-bound RNA was isolated and analyzed by qRT-PCR. Input RNA was extracted and served as the control.

2.15. Western blot assay

RIPA lysis buffer (Thermo Fisher Scientific, Shanghai, China) was used to lyse the OS cells to collect total protein [32]. The protein concentration was determined using a bicinchoninic acid (BCA) protein detection kit (Pierce, Rockford, IL, USA). After that, equal amounts of protein were isolated through sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto the polyvinylidene fluoride (PVDF) membrane. The membrane, after being blocked in 5% skimmed milk dissolved in Tris-buffered saline with Tween (TBST) for 1 h at room temperature, was incubated overnight with primary antibodies at 4°C, including anti-KLF9 antibody (1:1000, ab227920, Abcam, Shanghai, China), anti-E-cadherin antibody (1:1000, ab133597, Abcam, Shanghai, China), anti-N-cadherin antibody (1:1000, ab76011, Abcam, Shanghai, China), anti-Ago2 antibody (1:1000, ab186733, Abcam, Shanghai, China) and anti-GAPDH antibody (1:1000, ab128915, Abcam, Shanghai, China). After washing 3 times with TBST, the membrane and the diluted secondary antibody Goat Anti-Rabbit (1:1000, ab205718, Abcam, Shanghai, China) were incubated at room temperature for 1 h. After washing with TBST twice, a hypersensitive enhanced chemiluminescence (ECL) kit (GE Healthcare, Piscataway, NJ, USA) was utilized for developing the target protein bands. Eventually, we adopted the ImageJ software (NIH, Bethesda, Maryland, USA) to quantify the gray values of the protein bands.

2.16. Statistical analysis

SPSS 20.0 statistical software (SPSS Inc., Chicago, IL, USA) was the statistical analysis tool. Normality of data was evaluated by the Shapiro-Wilk normality test, and homoscedasticity was assessed by the Levene’s test. All experiments were repeated independently at least three times.
Data were expressed as mean ± standard deviation. The comparison of two groups was carried out via the independent-sample t-test, and one-way analysis of variance and Tukey’s post-hoc test were performed for the comparison of means of multiple groups. The relationship between circ_0078767 expression and OS overall survival was analyzed using Kaplan-Meier plot and log-rank test. Chi-square (χ²) test was used to analyze the relationship between the expression of circ_0078767 and the clinicopathological characteristics of OS patients. The correlation analysis was carried out via Pearson correlation’s analysis. P < 0.05 denoted a difference of statistical significance.

3. Results

This study explored the expression characteristics of circ_0078767 in OS tissues and cells. Subsequently, the effects of circ_0078767 on OS cell proliferation, migration, invasion, EMT and apoptosis were investigated. In addition, the interaction between circ_0078767 and the miR-889/KLF9 axis in OS was also investigated. This study showed that circ_0078767 inhibited OS progression by regulating the miR-889/KLF9 axis.

3.1. Circ_0078767 is downregulated in OS tissues and cells

By analyzing the GSE140256 dataset in the public gene chip database GEO, it was found that the expression of circ_0078767 in OS tissue samples was significantly lower than that in normal adjacent tissues (Figure 1(a,b)). Subsequently, circ_0078767 expression in OS tissues and cells was further detected by qRT-PCR, and it was revealed that circ_0078767 expression was significantly reduced in OS tissues and cells (Figure 1(c, d)). Moreover, it was indicated that its low expression was correlated with the increased T stage of OS (Table 3). Furthermore, circ_0078767 was mainly located in the cytoplasm of Saos2 and MG63 cells (Figure 1(e)). To verify the circular property of circ_0078767, RNase R assay and actinomycin D analysis were performed. The results showed that circ_0078767 was resistant to RNase R digestion (Figure 1(f)), and the half-life of circ_0078767 was longer than that of GAPDH mRNA (Figure 1(g)). Additionally, a survival analysis showed that low circ_0078767 expression was associated with shorter overall survival time of OS patients (Figure 1(h)). To decipher circ_0078767’s biological functions in OS, we selected MG63 cells with the highest circ_0078767 expression and Saos2 cells with the lowest circ_0078767 expression to establish cell models of circ_0078767 knockdown and overexpression, respectively, and the transfection was confirmed through qRT-PCR to be a success (Figure 1(i)). Ultimately, si-circ_0078767#2 with the highest efficiency of knockdown was chosen for follow-up research.

3.2. Circ_0078767 restrains OS cell growth, migration and invasion, and promotes apoptosis

To dig deeper into circ_0078767’s biological functions in OS cells, MTT, scratch healing and Transwell invasion assays were conducted for examining the effects that circ_0078767 had on OS cell growth, migration and invasion, respectively. MTT assay suggested that transfection of circ_0078767 overexpression plasmids significantly repressed Saos2 cell proliferation, while transfection of si-circ_0078767#2 facilitated MG63 cell proliferation (Figure 2(a)). Scratch healing and Transwell invasion assays revealed that circ_0078767 overexpression markedly inhibited Saos2 cell migration and invasion, but circ_0078767 knockdown boosted MG63 cell migration and invasion (Figure 2(b,c)). Furthermore, overexpression of circ_0078767 significantly increased E-cadherin expression and decreased N-cadherin expression in Saos2 cells compared with the control group (Figure 2(d)), whereas knockdown of circ_0078767 had the opposite effects (Figure 2(d)). TUNEL assay showed that overexpression of circ_0078767 significantly reduced the apoptosis of Saos2 cells, whereas knockdown of circ_0078767 increased the apoptosis of MG63 cells (Figure 2(e)). To further investigate the effect of circ_0078767 on OS progression in vivo, MG63 cells transfected with si-circ_0078767#2 or si-NC were transplanted into the lateral caudal vein of nude mice, respectively. As shown (Supplementary Figure S1), there were significantly more metastatic nodules in the mouse lung tissues of the si-circ_0078767#2/MG63
group compared with the si-NC/MG63 group. These results indicate that circ_0078767 can inhibit the progression of OS.

3.3. Circ_0078767 binds directly to miR-889

To clarify circ_0078767’s molecular mechanisms in OS, the Circular RNA Interactome database (https://circinteractome.nia.nih.gov/) was searched to predict circ_0078767’s downstream targets, and it was revealed that circ_0087862 and miR-889 had a potential binding sequence (Figure 3(a)). Dual-luciferase assay indicated that compared with the miR-NC group, transfection of miR-889 mimics markedly inhibited circ_0078767-WT’s luciferase activity, yet failed to significantly change that of circ_0078767-MUT (Figure 3(b)). RIP assay showed that in contrast with the IgG group, circ_0078767 was enriched in the Ago2 group (Figure 3(c)). Additionally, we found that Ago2 was mainly present in the RIP-Ago2 group, indicating that the RIP assay was successfully performed (Figure 3(d)). To further
Table 3. Correlation between patients’ clinicopathological features and circ_0078767 expression in osteosarcoma tissues.

| Clinicopathological status | Numbers | High [22] | Low [22] | $\chi^2$ | $P$ value |
|----------------------------|---------|-----------|----------|---------|----------|
| Age (years)                |         |           |          |         |          |
| <18                        | 26      | 10        | 16       |         |          |
| $\geq$18                   | 18      | 12        | 6        | 3.385   | 0.066    |
| Gender                     |         |           |          |         |          |
| Male                       | 27      | 14        | 13       |         |          |
| Female                     | 17      | 8         | 9        | 0.096   | 0.757    |
| T stage                    |         |           |          |         |          |
| I-II                       | 23      | 15        | 8        |         |          |
| III-IV                     | 21      | 7         | 14       | 4.464   | 0.035*   |
| Tumor size (cm)            |         |           |          |         |          |
| $\leq$5                    | 24      | 13        | 11       | 0.367   | 0.545    |
| $>$5                       | 20      | 9         | 11       |         |          |
| Location                   |         |           |          |         |          |
| Femur/tibia                | 32      | 14        | 18       | 1.833   | 0.176    |
| Elsewhere                  | 12      | 8         | 4        |         |          |
| Distant metastasis         |         |           |          |         |          |
| Present                    | 26      | 14        | 12       | 0.376   | 0.540    |
| Absent                     | 18      | 8         | 10       |         |          |

* $P < 0.05.$

confirm the direct interaction between circ_0078767 and miR-889, we performed a biotin-labeled RNA pull-down assay. As expected, the bio-miR-889 probe captured more circ_0078767 compared with the bio-miR-NC probe (Figure 3(e)). Furthermore, it was revealed that circ_0078767 overexpression suppressed miR-889 expression in OS cells, while knockdown of circ_0078767 elevated miR-889 expression (Figure 3(f)). Also, qRT-PCR was employed to evaluate miR-889 expression in OS tissues and cells, and it was unveiled that miR-889 was highly expressed in OS tissues and cell lines (Figure 3(g,h)). Pearson correlation analysis showed that circ_0078767 and miR-889 expressions in OS tissues were inversely correlated (Figure 3(h)). These findings demonstrate that circ_0078767 can directly target miR-889 and negatively modulate its expression.

3.4. Circ_0078767 inhibits OS cell growth, migration and invasion and promotes apoptosis via targeting miR-889

To ascertain whether circ_0078767 exerts the biological functions via miR-889, miR-889 inhibitors were transfected into MG63 cells transfected with si-circ_0078767#2, and miR-889 mimics were transfected into Saos2 cells overexpressing circ_0078767, and the transfection was validated via qRT-PCR to be successful (Figure 4(a)). Then, MTT, scratch healing, Transwell invasion and Western blot assays were utilized to examine Saos2 and MG63 cell growth, migration, invasion and EMT, and it was demonstrated that the transfection of miR-889 mimics partly counteracted the inhibitory effect that circ_0078767 overexpression had on Saos2 cell growth, migration, invasion and EMT (Figure 4(b–g)); the promoting impact of circ_0078767 knockdown on MG63 cell growth, migration and invasion was partly reduced by the transfection of miR-889 inhibitors (Figure 4(b–g)). In addition, TUNEL assay showed that miR-889 mimics attenuated the promoting effect of circ_0078767 overexpression on Saos2 cell apoptosis (Figure 4(h)); the inhibitory effect of circ_0078767 knockdown on MG63 cell apoptosis was significantly reversed by miR-889 inhibitors (Figure 4(h)). The aforementioned evidence suggests that circ_0078767 can restrain OS cell growth and metastasis via sponging miR-889.

3.5. KLF9 is miR-889’s direct target and positively regulated by circ_0078767

The starBase (http://starbase.sysu.edu.cn/index.php) database shows that there exists a binding sequence between KLF9 3’-UTR and miR-889 (Figure 5(a)). The dual-luciferase assay results showed that the transfection of miR-889 mimics remarkably suppressed KLF9-WT’s luciferase activity, but failed to significantly affect that of KLF9-MUT (Figure 5(b)). Furthermore, it was revealed that as against the NC group, circ_0078767 overexpression up-regulated KLF9 mRNA and protein expression levels in OS cells, while co-transfection of miR-889 mimics partially weakened this effect (Figure 5(c,d)); transfection of si-circ_0078767#2 suppressed KLF9 mRNA and protein expression levels, yet co-transfection of miR-889 inhibitors partially counteracted this effect (Figure 5(e,f)). Additionally, qRT-PCR suggested that in OS tissues KLF9 mRNA expression was down-regulated (Figure 5(g)). In addition, Pearson correlation analysis showed that KLF9 mRNA and miR-889 expressions were inversely correlated in OS tissues, and circ_0078767 and KLF9 mRNA expressions were positively correlated (Figure 5(h,i)). These findings confirm that
circ_0078767 upregulates KLF9 via inhibiting miR-889.

3.6. KLF9 overexpression reverses the effect of circ_0078767 knockdown on OS cells

To investigate whether circ_0078767 is involved in OS progression by regulating KLF9, we first transfected KLF9 overexpression plasmid and its control (NC) into MG63 cells. The results showed that KLF9 was significantly up-regulated in MG63 cells transfected with KLF9 overexpression plasmid compared with the NC group (Figure 6(a)). Then, KLF9 overexpression plasmid was transfected into MG63 cells with circ_0078767 knockdown, and the transfection efficiency was detected by qRT-PCR and Western blot. It was found that overexpression of KLF9 reversed the inhibitory effect of circ_0078767 knockdown on KLF9 mRNA and protein in MG63 cells (Figure 6(b,c)). Furthermore, the promoting effect of circ_0078767 knockdown on OS cell proliferation, migration, invasion and EMT was significantly attenuated by KLF9 overexpression (Figure 6(d,g)). In addition, KLF9 overexpression could also reverse the inhibitory effect of circ_0078767 knockdown on MG63...
cell apoptosis (Figure 6(h)). This suggests that circ_0078767 can inhibit OS progression by regulating KLF9 expression.

4. Discussion

CircRNAs are covalently closed non-coding RNAs without 3' tail and 5' cap ends, which makes circRNAs more stable compared with linear RNAs [33,34]. CircRNAs play various key roles in biological processes as miRNA sponges, protein scaffold or guider, and some of them can encode peptides [35]. Increasing studies suggest that circRNAs are promising to be used in the early diagnosis, prognosis prediction, and even gene therapy of malignancies [36]. Plenty of studies have reported that circRNAs feature prominently in various malignancies including OS [37]. For instance, low circHIPK3 expression suggests shorter overall survival time of OS patients, and circHIPK3 overexpression noticeably suppresses OS cell growth, migration and invasion [38]; in OS tissues circ_0000285 is highly expressed and circ_0000285 overexpression enhances OS cell migration and proliferation capabilities [39]. It is reported that circ_0078767 is downregulated in non-small cell lung carcinoma tissues, and over-expression of circ_0078767 can dramatically inhibit non-small cell lung carcinoma cell viability, block cell cycle progression, inhibit cell invasion and migration, and induce the apoptosis [40], which indicates the tumor-suppressing property of circ_0078767. We first demonstrated that in OS tissues and cells circ_0078767 was under-expressed, and low circ_0078767 expression was linked to OS patients’ increased T stage and
shorter overall survival. Additionally, up-regulating circ_0078767 expression significantly repressed OS cell growth, migration, invasion, EMT, and promoted apoptosis, while circ_0078767 knockdown had the opposite effects. These findings indicate that circ_0078767 has the potential to be implicated in OS tumorigenesis and progression.

MiRNAs, as tumor-promoting or tumor-suppressing factors, play an important regulatory role in multiple malignancies [41–43]. Previous research has indicated that many miRNAs partake in modulating the malignant phenotypes of OS cells [44]. For example, miR-708 takes part in inhibiting OS cell growth and facilitating the apoptosis via targeting CUL4B [45]; miR-411 expression is increased in OS cells, and miR-411 mimic facilitates OS cell proliferation and migration [46]. MiR-889 has been confirmed to play a key regulatory part in multiple tumors. Reportedly, up-regulated expression of miR-889 facilitates cell cycle progression in esophageal squamous cell cancer [47]; miR-889 promotes colorectal carcinoma cell growth via targeting DAB2IP [48]; miR-889-3p is high-expressed in OS cells and tissues, and miR-889-3p promotes OS cell proliferation by...
repressing MNDA expression [14]. Moreover, quite a few studies demonstrate that circRNAs can serve as miRNAs’ competing endogenous RNAs to play a regulatory role. For example, circ_0102049 absorbs miR-1304-5p and up-regulates MDM2 at the post-transcriptional level, thereby promoting OS cell growth, migration and invasion [49]; circTADA2A increases CREB3 expression by sponging miR-203a-3p to facilitate OS tumorigenesis and progression [9]. In this study, bioinformatics analysis indicated that miR-889 and circ_0078767 had a complementary sequence. It was further confirmed that circ_0078767 could absorb miR-889 to repress its expression, thus restraining OS cell proliferation, migration, invasion and EMT, and promoting the apoptosis.

KLF9 belongs to the SP/KLF family [50]. The KLF family members participate in regulating cell differentiation, proliferation and apoptosis by
Figure 6. Circ_0078767 inhibits OS progression by regulating KLF9.

(a). Western blot was used to detect the expression level of KLF9 in MG63 cells transfected with KLF9 overexpression plasmid and control plasmid.(b&c). Western blot was used to detect the expressions of KLF9 mRNA and protein in MG63 cells after transfection of si-circ_0078767#2 or/and KLF9 overexpression plasmid.(d). Detection of MG63 cell proliferation after transfection of si-circ_0078767#2 or/and KLF9 overexpression plasmid by MTT assay.(e). Detection of MG63 cell migration after transfection of si-circ_0078767#2 or/and KLF9 overexpression plasmid by scratch wound healing assay. Scale bars, 100 μm.(f). Detection of MG63 cell invasion after transfection of si-circ_0078767#2 or/and KLF9 overexpression plasmid by Transwell invasion assay. Scale bars, 250 μm. (g). Western blot was used to detect the expression levels of E-cadherin and N-cadherin in MG63 cells transfected with si-circ_0078767#2 or/and KLF9 overexpression plasmid.(h). TUNEL assay was used to detect the apoptosis of MG63 cells after transfection of si-circ_0078767#2 or/and KLF9 overexpression plasmid. Scale bars, 250 μm. Each experiment was carried out in triplicate. **p < 0.01, ***p < 0.001.
binding to the GC-GT-enriched region in the promoter/enhancer [51]. KLF9 is considered to be a tumor-suppressive gene, and KLF9 is downregulated in non-small cell lung cancer, breast cancer, colorectal cancer and other cancers, and KLF9 partakes in inhibiting the malignant phenotypes of cancer cells [52–54]. Moreover, KLF9 is reportedly under-expressed in OS cells and tissues and it participates in modulating the malignant progression of OS [55,56]. Reportedly, miR-889 targets KLF9 in non-small cell lung cancer and breast cancer cells [17,18]. Similarly, this study proved that miR-889 could target KLF9 in OS cells. Also, KLF9 was confirmed to be high-expressed in OS tissues, and circ_0078767 positively modulated KLF9 expression by targeting miR-889. In addition, KLF9 overexpression could reverse the effects of circ_0078767 knockdown on OS cell growth, migration, invasion, EMT and apoptosis. The aforementioned evidence indicates that circ_0078767 upregulates KLF9 via sponging miR-889, thus participating in the malignant progression of OS.

5. Conclusion

In a nutshell, circ_0078767 up-regulates KLF9 by sponging miR-889 in OS, thus restraining OS cell growth, migration and invasion. Our study has offered a new theoretical foundation for the molecular mechanism underlying OS progression.

List of abbreviations

| Abbreviation | Description |
|--------------|-------------|
| OS | osteosarcoma |
| Circs / circRNAs | circular RNAs |
| EMT | epithelial-mesenchymal transition |
| miRs / miRNAs | microRNAs |
| 3′-UTR | 3′-untranslated region |
| KLF9 | Kruppel-like factor 9 |
| BTEB1 | basic transcription element-binding protein 1 |
| GEO | Gene Expression Omnibus |
| FBS | fetal bovine serum |
| NC | empty plasmid |
| siRNA | small interfering RNA |
| si-NC | siRNA negative control |
| miR-NC | mimics control |
| miR-in | inhibitors control |
| qRT-PCR | quantitative real-time polymerase chain reaction |
| cDNA | complementary DNA |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase |
| RNase R | ribonuclease R |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| OD | optical density |
| PBS | phosphate buffer saline |
| TUNEL | terminal deoxynucleotidyl transferase-mediated nick end labeling |
| DAPI | 4′,6-diamidino-2-phenylindole |
| HE | hematoxylin-eosin |
| Wild type | WT |
| Mutant | MUT |
| RIP | RNA immunoprecipitation |
| RIPA | radio-immunoprecipitation assay |
| Ago2 | argonaute 2 protein |
| IgG | immunoglobulin G |
| BCA | bicinchoninic acid |
| PVDF | polyvinylidene fluoride |
| TBST | Tris-buffered saline with Tween |
| ECL | enhanced chemiluminescence |
| x² | chi-square |

Author’s contributions

Conceived and designed the experiments: HSZ; Performed the experiments: QC and WHR; Analyzed the data: QC and HSZ; Wrote the paper: QC and HSZ. All authors have read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Ethics statement

The procedures of clinical sample collection and the corresponding experiments were reviewed and endorsed by the Ethics Review Board of Yangzhou University (Approval No. YZUHL2019008). All procedures and experiments were conducted following the Declaration of Helsinki.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

ORCID

Haisen Zhou @ http://orcid.org/0000-0003-3087-4270

Data availability statement

The data used for supporting the findings of this study are available from the corresponding authors upon request.
References

[1] Simpson E, Brown HL. Understanding osteosarcomas. JAAPA. 2018;31(8):15–19.
[2] Biazzo A, De Paolis M. Multidisciplinary approach to osteosarcoma. Acta Orthop Belg. 2016;82(4):690–698.
[3] Harrison DJ, Geller DS, Gill JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50.
[4] Xie L, Pan Z. Circular RNA circ_0000467 regulates colorectal cancer development via miR-382-5p/EN2 axis. Bioengineered. 2021 Dec;12(1):886–897.
[5] Wang Y, Liu J, Ma J, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019 Jul 5;18(1):116.
[6] Yang F, Hu A, Li D, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. 2019 Nov 13;18(1):158.
[7] Luo GC, Chen L, Fang J, et al. Hsa_circ_0030586 promotes epithelial-mesenchymal transition in prostate cancer via PI3K-AKT signaling. Bioengineered. 2021 Dec;12(2):11089–11107.
[8] Jin J, Chen A, Qiu W, et al. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. J Cell Biochem. 2019 Sep;120(9):15678–15687.
[9] Wu Y, Xie Z, Chen J, et al. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer. 2019 Apr 2;18(1):73.
[10] Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1–10.
[11] Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(3):3–11.
[12] Zhang J, Yan YG, Wang C, et al. MicroRNAs in osteosarcoma. Clin Chim Acta. 2015;444:9–17.
[13] Gong N, Gong M. MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma. Medicine (Baltimore). 2018;97(29):e11100.
[14] Ge D, Chen H, Zheng S, et al. Hsa-miR-889-3p promotes the proliferation of osteosarcoma through inhibiting myeloid cell nuclear differentiation antigen expression. Biomed Pharmacother. 2019 Jun;114:108819.
[15] Bagati A, Moparthy S, Fink EE, et al. KLF9-dependent ROS regulate melanoma progression in stage-specific manner. Oncogene. 2019 May;38(19):3585–3597.
[16] Liu Y, Han K, Cao Y, et al. KLF9 regulates miR-338-3p/NRCAM axis to block the progression of osteosarcoma cells. J Cancer. 2022 Mar 28;13(6):2029–2039.
[17] Han X, Tang Y, Dai Y, et al. MiR-889 promotes cell growth in human non-small cell lung cancer by regulating KLF9. Gene. 2019 May 30;699:94–101.
[18] Jin Y, Xu L, Zhao B, et al. Tumour-suppressing functions of the IncRNA MBNL1-AS1/miR-889-3p/KLF9 axis in human breast cancer cells. Cell Cycle. 2022 May;21(9):908–920.
[19] Lu Z, Wang C, Lv X, et al. Hsa_circ_0010220 regulates miR-198/syntaxin 6 axis to promote osteosarcoma progression. J Bone Oncol. 2021 Apr 22; 28:100360.
[20] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108.
[21] Wang H, Wang H, Cui W, et al. Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell procession in hepatocellular carcinoma. Diagn Pathol. 2021 Jun 11;16(1):51.
[22] Liu F, Zhang X, Wu F, et al. Hsa_circ_0088212-mediated miR-520 h/APOA1 axis inhibits osteosarcoma progression. Transl Oncol. 2021 Dec;14(12):101219.
[23] Nie C, Han J, Bi W, et al. Circular RNA circ_0006644 promotes papillary thyroid cancer progression via sponging miR-1205 and regulating E2F3 expression. Cell Cycle. 2022 Jan;21(2):126–139.
[24] Li S, Peng D, Yin ZQ, et al. Effect of DEC1 on the proliferation, adhesion, invasion and epithelial-mesenchymal transition of osteosarcoma cells. Exp Ther Med. 2020 Mar;19(3):2360–2366.
[25] Xu L, Shi L, Qiu S, et al. Design, synthesis, and evaluation of cyanopyridines as anti-colorectal cancer agents via inhibiting STAT3 pathway. Drug Des Devel Ther. 2019 Sep 24;13:3369–3381.
[26] Yu X, Gao X, Mao X, et al. Knockdown of FOXO6 inhibits glycolysis and reduces cell resistance to paclitaxel in HCC cells via PI3K/Akt signalling pathway. Onco Targets Ther. 2020 Feb 19;13:1545–1556.
[27] Chen X, Zhang Y, Zhang S, et al. Oleanderic acid inhibits osteosarcoma cell proliferation and invasion by suppressing the SOX9/Wnt1 signalling pathway. Exp Ther Med. 2021 May;21(5):443.
[28] Gong Z, Chen X, Zhang Y, et al. LncRNA GATA6-AS1 inhibits the progression of non-small cell lung cancer via repressing microRNA-543 to up-regulating RKIP. Cancer Manag Res. 2020 Sep 29;12:9327–9338.
[29] Wu Y, Shen Q, Chen X, et al. miR-1301-3p promotes the proliferation and migration of lung cancer cells via direct repression of polymerase I and transcript release factor. Oncol Lett. 2020 Dec;20(6):286.
[30] Zhang Y, Zhang Z, Yi Y, et al. CircNOL10 acts as a sponge of miR-135a/b-5p in suppressing colorectal cancer progression via regulating KLF9. Onco Targets Ther. 2020 Jun 8;13:5165–5176.
[31] Jiang LP, Wang SR, Chung HK, et al. miR-222 represses expression of zipcode binding protein-1 and phospholipase C-γ1 in intestinal epithelial cells. Am J Physiol Cell Physiol. 2019 Mar 1;316(3):C415–C423.
[32] Luo Z, Rong Z, Zhang J, et al. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression. Mol Cancer. 2020 May 9;19(1):86.
[33] Zhang HD, Jiang LH, Sun DW, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25 (1):1–7.

[34] Zhang YQ, Shao CC, Li CT, et al. Research progress of circRNA and its significance in forensic science. Fa Yi Xue Za Zhi. 2016;32(2):131–133.

[35] Ng WL, Mohd Mohidin TB, Shukla K. Functional role of circular RNAs in cancer development and progression. RNA Biol. 2018;15(8):995–1005.

[36] Wang Y, Mo Y, Gong Z, et al. Circular RNAs in human cancer. Mol Cancer. 2017;16(1):25.

[37] Bach DH, Lee SK, Sood AK. Circular RNAs in cancer. Mol Ther Nucleic Acids. 2019;16:118–129.

[38] Xiao-Long M, Kun-Peng Z, Chun-Lin Z. Circular RNA circ_HIPK3 is down-regulated and suppresses cell proliferation, migration and invasion in osteosarcoma. J Cancer. 2018;9(10):1856–1862.

[39] Long Z, Gong F, Li Y, et al. Circ_0000285 regulates proliferation, migration, invasion and apoptosis of osteosarcoma by miR-409-3p/IGFBP3 axis. Cancer Cell Int. 2020 Oct 6;20:481.

[40] Chen T, Yang Z, Liu C, et al. Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p. Cell Prolif. 2019;52(2):e12548.

[41] Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview. J Cell Physiol. 2018;233 (5):3846–3854.

[42] Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019;70:3–20.

[43] Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clin Chim Acta. 2020; 500:10–19.

[44] Otoukesh B, Abbasi M, Gorgani HO, et al. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma. Cancer Cell Int. 2020;20:254.

[45] Chen G, Zhou H. MiRNA-708/CUL4B axis contributes into cell proliferation and apoptosis of osteosarcoma. Eur Rev Med Pharmacol Sci. 2018;22(17):5452–5459.

[46] Xu N, Yang W, Liu Y, et al. MicroRNA-411 promoted the osteosarcoma progression by suppressing MTSS1 expression. Environ Sci Pollut Res Int. 2018;25 (12):12064–12071.

[47] Xu Y, He J, Wang Y, et al. miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS Lett. 2015;589(10):1127–1135.

[48] Xiao Y, Li ZH, Bi YH. MicroRNA-889 promotes cell proliferation in colorectal cancer by targeting DAB2IP. Eur Rev Med Pharmacol Sci. 2019;23(8):3326–3334.

[49] Jin Y, Li L, Zhu T, et al. Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma. Pathol Res Pract. 2019;215(12):152688.

[50] Tung B, Ma D, Wang S, et al. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells. BMC Cancer. 2018;18(1):1025.

[51] Isley MD, Huang S, Magor GW, et al. Corrupted DNA-binding specificity and ectopic transcription underpin dominant neomorphic mutations in KLF/SP transcription factors. BMC Genomics. 2019;20(1):417.

[52] Kong YJ, Tan XX, Zhang Y, et al. MiR-141 promotes cell proliferation and invasion in non-small cell lung cancer by targeting KLF9. Eur Rev Med Pharmacol Sci. 2019;23(23):10370–10378.

[53] Bai XY, Li S, Wang M, et al. Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion. Cancer Lett. 2018;412:224–235.

[54] Brown AR, Simmen RC, Raj VR, et al. Krüppel-like factor 9 (KLF9) prevents colorectal cancer through inhibition of interferon-related signaling. Carcinogenesis. 2015;36 (9):946–955.

[55] Jin Y, Yang L, Li X. MicroRNA-652 promotes cell proliferation and osteosarcoma invasion by directly targeting KLF9. Exp Ther Med. 2020;20(4):2953–2960.

[56] Peng N, Miao Z, Wang L, et al. MiR-378 promotes the cell proliferation of osteosarcoma through down-regulating the expression of Krüppel-like factor 9. Biochem Cell Biol. 2018;96(3):515–521.